Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Dec;6(4):398-406.
doi: 10.1007/s11764-012-0234-x. Epub 2012 Oct 4.

Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL Study

Adriana Villaseñor  1 , Rachel Ballard-Barbash, Kathy Baumgartner, Richard Baumgartner, Leslie Bernstein, Anne McTiernan, Marian L Neuhouser
Affiliations

Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL Study

Adriana Villaseñor et al. J Cancer Surviv. 2012 Dec.

Abstract

Purpose: This study aimed to determine the prevalence of sarcopenia and examine whether sarcopenia was associated with overall and breast-cancer-specific mortality in a cohort of women diagnosed with breast cancer (stages I-IIIA).

Methods: A total of 471 breast cancer patients from western Washington State and New Mexico who participated in the prospective Health, Eating, Activity, and Lifestyle Study were included in this study. Appendicular lean mass was measured using dual X-ray absorptiometry scans at study inception, on average, 12 months after diagnosis. Sarcopenia was defined as two standard deviations below the young healthy adult female mean of appendicular lean mass divided by height squared (<5.45 kg/m(2)). Total and breast-cancer-specific mortality data were obtained from Surveillance Epidemiology and End Results registries. Multivariable Cox proportional hazard models assessed the associations between sarcopenia and mortality.

Results: Median follow-up was 9.2 years; 75 women were classified as sarcopenic, and among 92 deaths, 46 were attributed to breast cancer. In multivariable models that included age, race-ethnicity/study site, treatment type, comorbidities, waist circumference, and total body fat percentage, sarcopenia was independently associated with overall mortality (hazard ratio (HR) = 2.86; 95 % CI, 1.67-4.89). Sarcopenic women had increased risk of breast-cancer-specific mortality, although the association was not statistically significant (HR = 1.95, 95 % CI, 0.87-4.35).

Conclusion: Sarcopenia is associated with an increased risk of overall mortality in breast cancer survivors and may be associated with breast-cancer-specific mortality. The development of effective interventions to maintain and/or increase skeletal muscle mass to improve prognosis in breast cancer survivors warrants further study.

Implications for cancer survivors: Such interventions may help breast cancer patients live longer.

PubMed Disclaimer

Conflict of interest statement

Disclosure of potential conflicts of interest No potential conflicts of interest were disclosed.

Figures

Fig. 1
Fig. 1
Overall survival curves of breast cancer survivors with and without sarcopenia
Fig. 2
Fig. 2
Breast-cancer-specific survival curves of breast cancer survivors with and without sarcopenia
See this image and copyright information in PMC

References

    1. Chen X, et al. Obesity and weight change in relation to breast cancer survival. Breast Cancer Res Treat. 2010;122(3):823–833. - PMC - PubMed
    1. Carmichael AR. Obesity and prognosis of breast cancer. Obes Rev. 2006;7(4):333–340. - PubMed
    1. Prado CM, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009;15(8):2920–2926. - PubMed
    1. Prado CM, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9(7):629–635. - PubMed
    1. Tan BH, et al. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res. 2009;15(22):6973–6979. - PubMed

Publication types